Clinical trials: Percutaneous Coronary Intervention Patients
Myocardial Infarction, STEMI
Intramyocardial Haemorrhage in Patients With Primary STEMI
The purpose of the study is to assess the frequency and intensity of intramyocardial haemorrhage in patients with primary STEMI and different reperfusion strategies.
- Conditions
- Myocardial Infarction, STEMI, Myocardial Necrosis, Myocardial Injury
- Trial name
- HaemInCor (NCT03677466)
- Testing
- Pharmaco-invasive strategy, Primary PCI
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Reperfusion Injury, Myocardial
The Role of Colchicine in Reducing The Rate of Myocardial Reperfusion Injury
The goal of this clinical trial is to investigate the role of colchicine in reducing the rate of myocardial reperfusion injury in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention.
- Trial name
- NCT05734612
- Testing
- Colchicine
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Universitas Indonesia
ST Segment Elevation Myocardial Infarction, Elective Percutaneous Coronary Intervention
Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI
Elective percutaneous coronary intervention (EPCI) is the common treatment of ST segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following EPCI in STEMI patients has been a serious and common…
- Trial name
- NOSLOWFLOW-Ⅱ (NCT03406832)
- Testing
- Nitroprusside Sodium, Tirofiban Hydrochloride, Heparinized saline
- Where
- 28 sites in China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin).
- Conditions
- Acute Coronary Syndrome, Percutaneous Coronary Intervention, Drug-Eluting Stents
- Trial name
- CHANGE DAPT (NCT03197298)
- Testing
- Clopidogrel, Ticagrelor
- Where
- Netherlands
- Volunteers
- 2,062 people
- Sponsor
- Thorax Centrum Twente
PCI Patients, Single Coronary Vessel Disease
Non-Invasive Coronary Functional Evaluation of Patients With Single-vessel Coronary Artery Disease
Persistent or recurrent angina after successful percutaneous coronary intervention (PCI) remains a common clinical problem, affecting approximately 20-30% of patients despite complete epicardial coronary revascularization.
- Trial name
- NICE-CAD-PCI (NCT07805187)
- Testing
- Coronary flow reserve assessed by Echocardiography
- Volunteers
- 32 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Coronary Atherosclerosis
Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction
The purpose of this study is to test whether SR123781A is a possible treatment for patients with acute coronary syndromes (heart attack) who are scheduled to undergo a percutaneous coronary intervention (PCI) within 48 hours…
- Trial name
- SHINE (NCT00123565)
- Testing
- Hexadecasaccharide (SR123781A)
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 1,257 people
- Sponsor
- Sanofi
Acute Myocardial Infarction
Effect of N-acetylcystein in Myocardial Infarction
We designed this study to evaluate the effect of N-acetylcystein on biomarkers of platelet activation , cardiac necrosis and coronary reperfusion in patients undergoing percutaneous coronary intervention.
- Trial name
- NCT01741207
- Testing
- N-acetylcystein
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Tehran University of Medical Sciences
Coronary Artery Disease
DRUG ELUTING STENT FOR DIABETIC PATIENTS IN CORONARY ARTERY DISEASE TREATMENT
Study Title A post market registry of Abluminus® sirolimus eluting coronary stent system for percutaneous intervention in patients with diabetes mellitus Purpose The purpose of this registry is to prospectively capture clinical…
- Trial name
- DEDICATE (NCT03509532)
- Testing
- PCI
- Where
- Italy
- Volunteers
- 5,000 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
ECMO, High-risk PCI
Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention
The goal of this multicenter, randomized trial is to compare standby cannulated ECMO versus prophylactic ECMO in patients undergoing high-risk percutaneous coronary intervention (PCI).
- Trial name
- ECMO-READY (NCT06274411)
- Testing
- Standby cannulated ECMO, Prophylactic ECMO
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Beijing Anzhen Hospital
Percutaneous Coronary Intervention
Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention
Background: Removal of femoral arterial catheter causes pain, and current interventions used for reducing this pain are not sufficiently effective.
- Trial name
- NCT03131271
- Testing
- cold application
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- TC Erciyes University
Acute Coronary Syndrome, Acute Myocardial Infarction
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- STOPDAPT-2 ACS (NCT03462498)
- Testing
- 1-months DAPT, 12-month DAPT
- Where
- Japan
- Volunteers
- 3,008 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Atrial Fibrillation, Myocardial Infarction
Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)
Aim of this study is to describe clinical and procedural characteristics of real-world population initiated on triple antithrombotic therapy (double antiplatelet therapy+anticoagulant) or double antithrombotic therapy (single…
- Conditions
- Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding, Coronary Disease
- Trial name
- TRIDUAL-PCI (NCT04291287)
- Testing
- Antithrombotic Agent
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Scientific Institute San Raffaele
Coronary Artery Disease (CAD), Acute Coronary Syndrome (ACS)
Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).
The use of dual antiplatelet therapy is considered standard of care in patients post percutaneous coronary intervention (PCI) with stenting.
- Trial name
- NCT01109784
- Testing
- prasugrel, clopidogrel
- Where
- Greece
- Volunteers
- 70 people
- Sponsor
- University of Patras
Acute ST Segment Elevation Myocardial Infarction
Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention
The aim of this study is to evaluate the effects of N-acetyl cysteine on major cardiac and cerebral events in patients undergoing primary percutaneous coronary intervention who have moderate to high risk for contrast induced…
- Trial name
- EASE-PRM-PCI (NCT01878344)
- Testing
- NAC, Saline
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Suleyman Demirel University
Coronary Artery Disease
Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Early stent thrombosis has been noted with increased frequency in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) who are treated with bivalirudin and clopidogrel.
- Trial name
- NCT01789814
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Tufts Medical Center
STEMI, Primary PCI
Early Administration of Heparin At FMC for PPCI of STEMI Patients
Heparin is the first choice of anticoagulation drug for primary PCI of STEMI patients. However, the priority of use of hepairn in first medical contact or in Cathlab has not yet studied.
- Trial name
- HELP-PCI (NCT05329155)
- Testing
- Heparin Sodium Injection
- Where
- China
- Volunteers
- 1,145 people
- Sponsor
- Renmin Hospital of Wuhan University
No-Reflow Phenomenon
Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
Predicting no reflow in ppci of STEMI patients using mean platelet volume together with STEMI clinical risk scores
- Trial name
- NCT04785209
- Testing
- Mean platelet volume, lymphocyte number, STEMI clinical risk scores
- Where
- Egypt
- Volunteers
- 640 people
- Sponsor
- Assiut University
Myocardial Infarction, Myocardial Ischemia
Salvage of Myocardial Infarction Documented by MRI in Patients Undergoing Rescue Percutaneous Coronary Intervention
Atherosclerotic disease is responsible for one third of all deaths annually and is a major cause of comorbidities. While atherosclerosis is by itself a benign disease, it often leads to complications such as acute myocardial…
- Trial name
- SAVEME (NCT02517255)
- Testing
- Cardiac Magnetic Resonance Imaging
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- Federal University of São Paulo
Myocardial Infarction (MI)
Efficacy of Montelukast on STEMl Patients
Acute myocardial infarction (AMI) is one of the leading causes of patient mortality worldwide. Each year, over 8 million people globally die from AMI, with approximately 30% of these cases being ST-segment elevation myocardial…
- Trial name
- NCT07320625
- Testing
- Montelukast
- Where
- 12 sites in China
- Volunteers
- 512 people
- Sponsor
- Shanghai Zhongshan Hospital
Acute Coronary Syndrome
Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol
To assess the effects of Xuesaitong soft capsules on platelet function, clinical efficacy, prognosis, and safety in the treatment of acute coronary syndrome, 400 patients with acute coronary syndrome who underwent PCI were…
- Trial name
- NCT06845254
- Testing
- Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences